By:
On:
In: Actions

The Union for Affordable Cancer Treatment is asking Sherry Lansing, the former Paramount CEO and current member of the Board of Regents of the University of California, to stop the Regents’ efforts to obtain a patent on the prostate cancer drug enzalutamide (brand name Xtandi) in India. On May 24th, 2017, UACT was joined by 56 civil society organizations and academic experts in sending a letter to Janet Napolitano, President of the University of California system, and the Board of Regents of the University of California, requesting that they withdraw their efforts to obtain a patent on enzalutamide in India. Neither Napolitano’s office nor theRead More →

By:
On:
In: Actions

On May 24, 2017, the Union for Affordable Cancer treatment and 56 civil society organizations and academic experts called Janet Napolitano, the President of the University of California, and the Board of Regents, “withdraw your efforts to obtain a patent on the prostate cancer drug enzalutamide (brand name Xtandi) in India.”  A PDF copy of the letter is available here: UACT-U-Cal-Xtandi-Patent-India-2017May24 The text of the letter is as follows: Janet Napolitano, University of California, Office of the President, 1111 Franklin Street, Oakland, CA 94607 via email: president@ucop.edu Board of Regents of the University of California, Office of the Secretary and Chief of Staff to the Regents, 1111 Franklin St., 12th floor, Oakland, CA 94607, via email:Read More →

By:
On:
In: Actions, Negotiations

On May 3, 2017,  UACT was among 29 civil society organizations and 33 health professionals, activists, and economists — including Nobel Prize laureate Joseph Stiglitz — asking delegates to the World Health Assembly (WHA) to support a feasibility study on the progressive delinkage of the costs of research and development from the price of cancer medicines. A copy of the letter is available here. WHA-letter-on-delinkage-study-3May2017Read More →